2026-01-29 2026-01-29 , online online, 1,990 € zzgl. MwSt. Claire Blaney https://www.forum-institut.de/seminar/26062001-hta-market-access-pricing-in-europe/referenten/26/26_06/26062001-hta,-market-access-pricing-in-europe_blaney-claire.jpg HTA, Market Access & Pricing in Europe

Gain a structured, practice-oriented overview of EU HTA, market access and pricing. The seminar covers the evolving EU pharma legislation, the interface between JCA and national HTA and country deep dives: UK & Ireland, Nordics, Germany, France and Italy,

Topics
  • European market access and pricing: 2026 context and EU pharma legislation
  • UK & Ireland: HTA processes (e.g., STA, QALY role), reforms and pricing implications
  • Nordics: HTA, payer decisions and conjunction with EU HTA
  • Germany: AMNOG today and JCA impact on pricing and access schemes
  • France: SMR/ASMR evaluation, pricing interface and early access pathways
  • Spain and Italy: stakeholders, HTA, negotiations/managed entry and value-based approaches, Role of MFN


Who should attend
This seminar is designed for professionals in the pharmaceutical industry working in market access, pricing, and HEOR.

Basic prior knowledge of the European pharmaceutical market is helpful but not mandatory for participation.
Aims and objectives
This seminar provides a practical, up-to-date overview of European HTA, market access and pricing for innovative medicines, including how evolving Joint Clinical Assessments (JCA) interact with national procedures and pricing decisions.

You will understand the implications of current legislative changes and their ripple effects across key markets, and how to translate them into robust access strategies and evidence plans. Country deep dives and case-based discussions help you benchmark approaches and anticipate payer expectations across Europe.
Your benefit

  • Gain a concise, structured picture of the 2026 European market access and pricing landscape.
  • Understand how Joint Clinical Assessments (JCA) will interface with national HTA and the consequences for pricing, patient access schemes and timelines.
  • Benefit from country deep dives (UK & Ireland, Nordics, Germany, France, Spain, Italy) to compare stakeholder roles, evidence standards and payer decision drivers.
  • Take away pragmatic insights on value communication, managed/early access options and forecasting considerations informed by recent reforms and practice trends.

26062001 HTA, Market Access & Pricing in Europe

HTA, Market Access & Pricing in Europe

Focus on innovative drugs

Benefits
  • Country-specific insights for UK/Ireland, Nordics, Germany, France, Spain, Italy
  • Impact of MFN
  • Officially certified according to ISO 9001 and ISO 21001

Webcode 26062001

Jetzt buchen

JETZT Buchen

Referenten


Alles auf einen Blick

Termin

09 - 10/06/2026

09 - 10/06/2026

Zeitraum

Day 1: 09:00 a.m - 05:00 p.m
Day 2: 09:00 a.m - 05:00 p.m

Day 1: 09:00 a.m - 05:00 p.m
Day 2: 09:00 a.m - 05:00 p.m
Veranstaltungsort

online

online

Gebühr
Your contact

Dr. Henriette Wolf-Klein
Head of Department

+49 6221 500-680
h.wolf-klein@forum-institut.de

Details

Gain a structured, practice-oriented overview of EU HTA, market access and pricing. The seminar covers the evolving EU pharma legislation, the interface between JCA and national HTA and country deep dives: UK & Ireland, Nordics, Germany, France and Italy,

Topics

  • European market access and pricing: 2026 context and EU pharma legislation
  • UK & Ireland: HTA processes (e.g., STA, QALY role), reforms and pricing implications
  • Nordics: HTA, payer decisions and conjunction with EU HTA
  • Germany: AMNOG today and JCA impact on pricing and access schemes
  • France: SMR/ASMR evaluation, pricing interface and early access pathways
  • Spain and Italy: stakeholders, HTA, negotiations/managed entry and value-based approaches, Role of MFN


Who should attend
This seminar is designed for professionals in the pharmaceutical industry working in market access, pricing, and HEOR.

Basic prior knowledge of the European pharmaceutical market is helpful but not mandatory for participation.

Aims and objectives

This seminar provides a practical, up-to-date overview of European HTA, market access and pricing for innovative medicines, including how evolving Joint Clinical Assessments (JCA) interact with national procedures and pricing decisions.

You will understand the implications of current legislative changes and their ripple effects across key markets, and how to translate them into robust access strategies and evidence plans. Country deep dives and case-based discussions help you benchmark approaches and anticipate payer expectations across Europe.

Your benefit

  • Gain a concise, structured picture of the 2026 European market access and pricing landscape.
  • Understand how Joint Clinical Assessments (JCA) will interface with national HTA and the consequences for pricing, patient access schemes and timelines.
  • Benefit from country deep dives (UK & Ireland, Nordics, Germany, France, Spain, Italy) to compare stakeholder roles, evidence standards and payer decision drivers.
  • Take away pragmatic insights on value communication, managed/early access options and forecasting considerations informed by recent reforms and practice trends.

Detailed programme

Day 1: 09:00 a.m - 05:00 p.m
Day 2: 09:00 a.m - 05:00 p.m

09:00 Welcome


09:15

Claire Blaney

Market Access & Pricing in Europe - setting the scene 2026
  • Impact of the pharmaceutical legislation and the EU biotech act on market access strategies
  • Global impact of pricing decisions (USA...) on EU pricing

09:45

Claire Blaney

United Kingdom & Ireland - HTA assessments and the consequences for Market Access & Pricing
  • UK: Single Technology Appraisals (STA) and FAD process; The role of QALYs and cost-effectiveness
  • UK: Innovative Medicines Fund and reforms
  • Patient Access (programs)
  • UK: EU-HTA impact on national decisions?
  • Ireland - national HTA procedure and consequences for the pricing

12:00 Discussion, coffee & lunch break


13:00

Hannah Norman

Nordic Markets - HTA, Market Access & Payers
  • HTA: Joint assessments and national decisions
  • National procedure & conjunction with EU-HTA
  • HTA accessments and the consequences for market access, pricing and payer decisions

15:00 Coffee break


15:30

Sebastian Vinzens

Germany - AMNOG & EU HTA - current status
  • AMNOG and the conjunction with EU HTA
  • Pricing
  • Patient access schemes

17:00 Ende of day one


09:00

Alain Estival

France - HTA, Market Access & Pricing
  • HTA: Clinical benefit (SMR) and added benefit (ASMR); Evaluation criteria and dossiers
  • Interaction with pricing processes
  • National procedure & conjunction with EU-HTA
  • Patient Access programs

11:00 Coffee break


11:30

Marta Taboada Rodríguez

Market Access & Pricing in Spain
  • Stakeholder in Spain
  • HTA process and the role of RWE
  • Negociation with SGCMPS
  • Patient Access Schemes
  • Price, volume & revenues forecasting
  • Changes in the evaluation process in Spain: what is already in place and what is expected to come (also with regard to EU HTA)

13:30 Lunch break


14:30

Bernd Schollmeier

Market Access & Pricing in Italy
  • Stakeholder in Italy
  • HTA processes and the conjunction with EU HTA
  • Managed Access Entry Agreements & Patient Access Schemes
  • Value based pricing approaches
  • Price, volume & revenues
  • MFN impact on Italian landscape

16:30 Discussion


17:00 End of day two


Ihr Nutzen

Technical requirements

You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.

We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.

Access to and procedure for online events

Once you have registered for an event, we will send you the access information for your customer portal. Click here to log in to the customer portal using your email address and password. Please ensure you can access the customer portal before the day of the event.

All important or additional information and personal documents are available in your personalised customer portal. This is also where you start your online courses. If you do not have access to the customer portal yet, you can easily register here.

On the day of the event, you kick off your online training in the customer portal by clicking ‘Participate’ directly in the respective event. You will then be redirected to the Learning Space.

Learn more about our online events here.

Free pre-meeting and technology check

You can attend one of our pre-meetings and explore our Learning Space free of charge. Registration is not required. You can find available dates for a pre-meeting in your customer portal. Click the green ‘Participate’ button in the pre-meeting in the customer portal and you will be redirected to the Learning Space.

The pre-meeting gives you the opportunity to explore our Learning Space and to familiarise yourself with the technology to start off your online training on the right foot. This is a non-binding offer for all our customers and not a prerequisite for participation. If a pre-meeting date does not suit you but you would still like a technology check, please contact us.

This distinguishes our events

of 5 stars of all ratings from 2025

of 5 stars on Trustpilot = good

Recommendations

Market Access Biosimilars 2026

Arzneimittelsteuerung bei Biosimilars in Deutschland - was kommt im Bereich Austausch, Substitution auf uns zu?

11.03.2026 in
Details

AMNOG 2026 in Zeiten von EU-HTA

Dieses Seminar umfasst AMNOG wie EU-HTA-Themen mit Informationen aus erster Hand von G-BA und IQWiG

25.02.2026 in
Details

Patient Involvement in HTA

This course offers a deep dive into patient involvement in HTA processes across Europe, with a focus on the UK and Germa...

19.03.2026 in
Details

Healthcare Management & Market Access-Lehrgang

In 2 Lehrgangstagen erhalten Sie profundes gesundheitspolitisches und gesundheitsökonomisches Know-how sowie Praxiswisse...

29. - 30.01.2026 in
Details

Key Account Management im regionalen Market Access

Seminar zur partnerschaftlichen Zusammenarbeit mit Krankenkassen und Ärzt*innen in der Versorgungsforschung und dem Vers...

19. - 20.03.2026 in
Details

Go forward

e-Learning - Click and learn

We provide flexible education and training with high-quality e-Learning programmes for several topics.

Details
e-Learning
In-house seminars

Our programmes are also available for in-house training. Just contact us!

Details
In-house seminars
We guarantee the highest quality

We are now officially certified to ISO 9001 and ISO 21001 standard.

Details
We guarantee the highest quality